Back to Search
Start Over
Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals
- Source :
- Journal of Diabetes Investigation, Vol 13, Iss 5, Pp 878-888 (2022)
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
-
Abstract
- ABSTRACT Aims/Introduction Metabolic dysfunction‐associated fatty liver disease (MAFLD), defined as hepatosteatosis with type 2 diabetes mellitus, overweight/obesity or metabolic dysregulation, has been proposed as a new feature of chronic liver disease. Fatty acid‐binding protein 4 (FABP4) is expressed in adipose tissue, and secreted FABP4 is associated with the development of insulin resistance and atherosclerosis. However, the relationship between MAFLD and FABP4 has not been fully addressed. Materials and Methods Associations of MAFLD with metabolic markers, including FABP4, fibroblast growth factor 21 and adiponectin, were investigated in 627 individuals (men/women 292/335) in the Tanno‐Sobetsu Study, a population‐based cohort. Results The mean age was 65 years (range 19–98 years, median [interquartile range] 68 [56–76] years). Hepatosteatosis was determined by the fatty liver index (FLI), and FLI ≥35 for men and FLI ≥16 for women were used for detection of fatty liver, as previously reported using 14,471 Japanese individuals. FLI was positively correlated with systolic blood pressure and levels of FABP4 (r = 0.331, P
Details
- Language :
- English
- ISSN :
- 20401124 and 20401116
- Volume :
- 13
- Issue :
- 5
- Database :
- Directory of Open Access Journals
- Journal :
- Journal of Diabetes Investigation
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9d32630c1daa4baabd03a63fcfb8afe3
- Document Type :
- article
- Full Text :
- https://doi.org/10.1111/jdi.13735